Want to see HK:1244 full AI Analyst Report?
Top Page
3D Medicines, Inc.
(1244)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$2.50
▼(-59.28% Downside)
Action:Reiterated
Date:05/19/26
The score is primarily held back by ongoing losses and persistent negative operating/free cash flow despite a high gross-margin profile and some improvement in loss levels. Technicals add pressure given the clear downtrend versus key moving averages and negative MACD. Valuation offers limited support because profitability is negative and no dividend yield is provided.
Positive Factors
High Gross Margin
A ~92% gross margin indicates strong unit economics and likely pricing power in its oncology portfolio. Durable high gross margins can fund R&D and commercialization as revenues scale, improving the chances of eventual operating profitability once top-line trends stabilize.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow (about -150M in 2025) shows the business consumes cash to run operations and advance its pipeline. Persistent cash burn increases dependence on external financing, raising dilution and execution risk over the medium term if revenue recovery lags.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A ~92% gross margin indicates strong unit economics and likely pricing power in its oncology portfolio. Durable high gross margins can fund R&D and commercialization as revenues scale, improving the chances of eventual operating profitability once top-line trends stabilize.
Read all positive factors
3D Medicines, Inc. (1244) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$653.19M
Dividend YieldN/A
Average Volume (3M)393.13K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth-20.21%
EPS Growth2.98%
CountryHK
Employees191
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding258,177,000
10 Day Avg. Volume535,000
30 Day Avg. Volume393,126
Financial Highlights & Ratios
PEG Ratio1.66
Price to Book (P/B)1.97
Price to Sales (P/S)3.30
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
3D Medicines, Inc. Business Overview & Revenue Model
Company Description
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is...
How the Company Makes Money
null...
3D Medicines, Inc. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
54
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 356.09M | 445.65M | 634.95M | 567.39M | 60.26M |
| Gross Profit | 298.97M | 371.74M | 524.01M | 525.18M | 55.98M |
| EBITDA | -197.43M | -226.95M | -529.23M | -1.03B | -1.45B |
| Net Income | -177.53M | -182.66M | -524.70M | -1.02B | -1.43B |
Balance Sheet | |||||
| Total Assets | 936.64M | 1.22B | 1.43B | 1.33B | 1.06B |
| Cash, Cash Equivalents and Short-Term Investments | 438.10M | 840.98M | 996.58M | 942.03M | 824.48M |
| Total Debt | 152.85M | 237.62M | 282.43M | 175.70M | 3.15B |
| Total Liabilities | 391.54M | 512.54M | 558.20M | 436.65M | 3.33B |
| Stockholders Equity | 596.98M | 785.06M | 936.74M | 943.00M | -2.24B |
Cash Flow | |||||
| Free Cash Flow | -149.87M | -249.60M | -150.74M | -332.76M | -433.46M |
| Operating Cash Flow | -149.85M | -210.58M | -144.41M | -278.78M | -377.08M |
| Investing Cash Flow | -26.20M | 17.95M | -187.58M | -242.11M | -98.87M |
| Financing Cash Flow | -89.56M | -33.92M | 304.51M | 408.41M | 840.08M |
3D Medicines, Inc. Technical Analysis
Negative
6.14
Price Trends
3.20
Negative
3.64
Negative
4.86
Negative
Market Momentum
-0.19
Positive
31.67
Neutral
24.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Negative. The current price of 6.14 is above the 20-day moving average (MA) of 2.86, above the 50-day MA of 3.20, and above the 200-day MA of 4.86, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 31.67 is Neutral, neither overbought nor oversold. The STOCH value of 24.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1244.
3D Medicines, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$6.77B | -55.90 | -6.26% | ― | -11.65% | -169.40% | |
44 Neutral | HK$653.19M | -3.04 | -27.04% | ― | -20.21% | 2.98% | |
44 Neutral | HK$8.59B | -68.31 | -11.21% | ― | 219.26% | 87.63% | |
43 Neutral | HK$505.82M | -3.93 | 191.92% | ― | -100.00% | 77.06% | |
42 Neutral | HK$666.77M | -1.05 | -75.15% | ― | 79.76% | 6.45% | |
42 Neutral | HK$525.38M | -2.27 | -28.13% | ― | -33.80% | 31.52% |
* Healthcare Sector Average
HK:1244
3D Medicines, Inc.
2.53
-1.56
-38.14%
HK:9966
Alphamab Oncology
6.95
0.85
13.93%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
1.60
-1.28
-44.44%
HK:2171
CARsgen Therapeutics Holdings Ltd.
14.26
-7.04
-33.05%
HK:2257
Sirnaomics Ltd.
4.61
-0.03
-0.65%
HK:6628
Transcenta Holding Limited
1.18
-0.28
-19.18%
3D Medicines, Inc. Corporate Events
3D Medicines Shareholders Approve All AGM Resolutions, Expand Capital Mandates
Jun 30, 2026
Shareholders of 3D Medicines Inc. approved all resolutions at the company’s annual general meeting held in Beijing on June 30, 2026, including the adoption of the 2025 audited financial statements and the re-election of key board members. Th...
3D Medicines consolidates company secretary and authorised representative roles
Jun 30, 2026
3D Medicines Inc. has announced that the Hong Kong Stock Exchange has confirmed current joint company secretary Xia Fang as fully qualified to serve as company secretary under the relevant listing rules, ending a prior waiver period tied to her qu...
3D Medicines Sets 2026 AGM to Approve Results, Board Changes and Share Mandate
Jun 5, 2026
3D Medicines Inc. has called its annual general meeting for June 30, 2026, in Beijing, where shareholders will vote on adopting the audited financial statements for the year ended December 31, 2025, and receive reports from the board and the audit...
3D Medicines’ Envafolimab Trial in Biliary Tract Cancer to Headline 2026 ASCO Meeting
May 27, 2026
3D Medicines Inc. announced that key results from its Phase III pivotal trial of envafolimab plus GEMOX as a first-line treatment for advanced biliary tract cancer have been selected for official presentation at the 2026 ASCO Annual Meeting. Envaf...
3D Medicines Completes Phase III Envafolimab Lung Cancer Trial Enrollment Ahead of Schedule
May 21, 2026
3D Medicines Inc. has announced early completion of patient enrollment in a randomized, double-blind, multi-center Phase III trial of envafolimab for neoadjuvant and adjuvant treatment of resectable Stage III non-small cell lung cancer. Conducted ...
3D Medicines Extends HK$50 Million Note to Puxin, Flags Disclosure Lapse
Apr 1, 2026
3D Medicines Inc., through its wholly owned Hong Kong subsidiary, has extended a HK$50 million unsecured short-term note to Puxin International Co., Ltd. at an unchanged annual coupon rate of 5.5%, pushing the maturity out to March 13, 2027 and fu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.